Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765063 +/- Ezabenlimab in Solid Tumors
NCT03990233Phase 1Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Apr 2019
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of BI 765063 in solid tumor, colorectal cancer (CRC) and endometrial cancer (EC) (4 arms), sponsored by OSE Immunotherapeutics. Primary endpoints: Number of patients with Dose-Limiting Toxicities at 3 weeks, Maximum Tolerated Dose determination at 3 weeks and 1 more. Started Apr 2019; status: completed.
02
Drugs
BI 765063
03
Conditions
solid tumorcolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03990233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990233.